Spremembe v zdravljenju raka v otroštvu in tveganje za sekundarne maligne neoplazme

Česen Mazić, Maja (avtor), Zadravec Zaletel, Lorna (mentor), Jazbec, Janez (komentor)

Namen dela: Z raziskavo smo želeli oceniti stopnjo tveganja in vrsto sekundarnih malignih neoplazem (SMN) pri osebah, zdravljenih zaradi raka v otroštvu ter povezavo s spremembami v zdravljenju. Preiskovanci in metode dela: V populacijsko raziskavo smo vključili 3271 oseb, ki so bile zdravljene zaradi raka v otroštvu do vključno 18. leta starosti v Sloveniji med letoma 1961 in 2013. Standardizirana incidenčna stopnja (SIR), absolutno presežno tveganje (AER) in kumulativna incidenca so glavni statistični kazalci, s katerimi smo opisali rezultate raziskave. Rezultati: V povprečnem času opazovanja 23.2 let je 230 oseb razvilo 273 sekundarnih neoplazem (SN), od tega 183 SMN, 34 meningeom in 56 ne-melanomski rak kože. Ti bolniki so bili v 10.5% zdravljeni z radioterapijo, v 31% s kemoterapijo, v 26.9% s kombinacijo kemoterapije in radioterapije in v 16.1% z operacijo. Tveganje za SMN je bilo skoraj 3-krat večje kot v splošni populaciji (SIR 2.9; 95%CI 2.5-3.3) in je ostalo 2-krat večje tudi po dopolnjenem 50. letu starosti (SIR 2.0; 95%CI 1.3-3.1). Kumulativna incidenca SMN 30 let po diagnozi raka v otroštvu je nižja za bolnike zdravljene pred letom 1970 (Pheterogenost<0.001). Kumulativna incidenca SMN je 40 let po diagnozi raka v otroštvu najnižja za bolnike zdravljene le z operacijo. Kljub manjši obremenitvi z obsevanjem po letu 1995, ni razlike v kumulativni incidenci SMN 15 let po diagnozi raka v otroštvu med obema skupinama bolnikov (Pepe Morijev test, p=0.11). Po dopolnjenem 40. letu starosti 80% vseh presežnih primerov SMN predstavljajo karcinomi ščitnice, dojke, tumorji osrednjega živčevja, karcinomi sečil in spolovil ter dihal. Tveganje za sekundarno levkemijo (SL) je v naši raziskavi 6-krat večje kot v splošni populaciji. Tveganje za SL je izenačeno, ne glede na čas diagnoze otroškega raka. Dve tretjini bolnikov je zbolelo za SL v prvih petih letih po diagnozi raka v otroštvu. Zaključki: Tveganje za SMN je pri osebah, zdravljenih zaradi raka v otroštvu, primerljivo s tistim v drugih populacijskih raziskavah. Presežno tveganje je po dopolnjenem 40. letu manjše zaradi naraščanja števila malignih neoplazem v splošni populaciji in dejstva, da je bil znaten del bolnikov v tej skupini zdravljen le z operacijo ali manj intenzivno kemoterapijo in radioterapijo. Kljub manjšemu deležu obsevanih otrok po letu 1995, ni razlike v kumulativni incidenci SMN 15 let po diagnozi otroškega raka v primerjavi z obdobjem pred letom 1995. Z daljšim časom opazovanja in naraščajočo starostjo oseb v kohorti narašča delež bolnikov s sekundarnimi karcinomi. Tveganje za SL je večje kot v ostalih raziskavah, saj smo vključili vse primere SL in je izenačeno ne glede na čas diagnoze otroškega raka.

• Jezik: Slovenski jezik
• Ključne besede: sekundarne maligne neoplazme, rak v otroštvu, Slovenija
• Vrsta gradiva: Doktorsko delo/naloga
• Organizacija: MF - Medicinska fakulteta
• Leto izida: 2023
• PID: 20.500.12556/RUL-144739
• COBISS.SI-ID: 147053571
• Datum objave v RUL: 10.03.2023

ČESEN MAZIĆ, Maja, 2023, Spremembe v zdravljenju raka v otroštvu in tveganje za sekundarne maligne neoplazme [na spletu]. Doktorska disertacija. [Dostopano 7 april 2025]. Pridobljeno s: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=slv&id=144739

Sekundarni jezik

• Jezik: Angleški jezik
• Naslov: Trends in treatment of childhood cancer and subsequent malignant neoplasm risk

Izvleček

Objective: The aim of the study was to investigate long-term risk and spectrum of subsequent neoplasm (SN) in childhood cancer survivors and to identify how trends in therapy influenced cumulative incidence of SN. Materials and methods: The population-based cohort comprises 3271 childhood cancer patients diagnosed in Slovenia aged ⡤ 18 years between 1st January 1961 and 31st December 2013 with a follow-up through 31st December 2018. Main outcome measures are standardized incidence ratios (SIRs), absolute excess risks (AERs), and cumulative incidence of SN. Results: After median follow-up time of 23.2 years, 230 patients experienced 273 SN, including 183 subsequent malignant neoplasm (SMN), 34 meningiomas and 56 nonmelanoma skin cancers. 10.5% patients received radiotherapy only, 31% chemotherapy only, 26.9% a combination of chemotherapy and radiotherapy and 16.1% surgery only. The overall risk for SMN was almost 3 times more than expected (SIR 2.9; 95%CI 2.5-3.3), with survivors still at 2-fold increased risk after attained age 50 years. The observed cumulative incidence of SMN at 30-years after diagnosis was lower for those diagnosed in 1960s, compared with the 1970s and the 1980s (Pheterogeneity<0.001). The observed cumulative incidence of SMN at 40-years after diagnosis was significantly lower for those treated with surgery only compared to chemotherapy and/or radiotherapy (Pheterogeneity<0.001). Despite reduced use of radiotherapy over time, there was no difference in cumulative incidence of SMN 15 years after diagnosis of childhood cancer for patients treated before or after 1995 (Pepe Mori's test, p = 0.11). After attained 40 years of age thyroid, genitourinary, breast, CNS and respiratory tumors were responsible for 80% of the total AER. Compared to general population, childhood cancer survivors had a 6-fold overall increased risk of secondary leukemia (SL). No difference in risk of SL was observed regarding time of diagnosis of childhood cancer. Two thirds of patients developed SL within first 5 years of childhood cancer diagnosis. Conclusions: Our study reports almost 3-fold increase in SMN among survivors of childhood cancer compared with general population. The SIRs reported by attained age are like other population-based studies. SIR is decreasing with attained age because of a fact that survivors treated long time ago received treatments with minimal carcinogenic potential. With longer follow up time proportion of patients diagnosed with subsequent carcinomas increases. Despite reduced use of radiotherapy after 1995 no difference in cumulative incidence of SMN 15 years after diagnosis of childhood cancer was observed. Risk for SL was greater in our cohort than in other published series due to inclusion of all cases of SL. Risk for SL was not different regardless of time of diagnosis of childhood cancer.

• Ključne besede: subsequent malignant neoplasm, childhood cancer, Slovenia